Several innovative therapies are revolutionizing glucose management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide standing out promising candidates. Retatrutide, a dual GIP and GLP-1 target stimulant, demonstrates significant weight loss and enhanced glycemic regulation. Cagrilli